Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 10:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 16,113 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Disorders Clear all
Completed Phase 2 Interventional

A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast Cancer

NCT00191672
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Gemcitabine, Paclitaxel, Docetaxel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
2
States / cities
Nashville, Tennessee • Katy, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2007 · Synced Oct 27, 2026, 10:53 PM EDT
Active, not recruiting Phase 4 Interventional

Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease

NCT06649539
View directory record Official record
Conditions
Peyronie Disease
Interventions
Collagenase Clostridium Histolyticum, RestoreX, Sildenafil
Drug · Device
Lead sponsor
Charitable Union for the Research and Education of Peyronie's Disease
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Orem, Utah
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 27, 2026, 10:53 PM EDT
Not listed Phase 1 Interventional

Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

NCT05539157
View directory record Official record
Conditions
Cutaneous Tumor, Malignant Solid Tumor
Interventions
JCXH-211
Drug
Lead sponsor
Immorna Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 27, 2026, 10:53 PM EDT
Completed Phase 4 Interventional Results available

Low Level Laser Treatment and Breast Cancer Related Lymphedema

NCT00852930
View directory record Official record
Conditions
Lymphedema
Interventions
laser and MLD combined, laser alone, manual lymphatic drainage
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
21 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 27, 2026, 10:53 PM EDT
Recruiting Phase 1 Interventional

A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

NCT06908928
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
bulumtatug fuvedotin
Drug
Lead sponsor
Mabwell (Shanghai) Bioscience Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Duarte, California • La Jolla, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 27, 2026, 10:53 PM EDT
Completed No phase listed Observational

Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer

NCT03981705
View directory record Official record
Conditions
TN ER-/PR-/HER2- Breast Cancer, Triple Negative Breast Cancer, HER2-positive Breast Cancer, ERany/PRany/HER2+ Breast Cancer
Interventions
Standard Trimodality Breast Imaging
Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 27, 2026, 10:53 PM EDT
Recruiting Not applicable Interventional

Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade

NCT07661966
View directory record Official record
Conditions
Melanoma (Skin Cancer), NSCLC (Non-small Cell Lung Cancer)
Interventions
Bright Light Therapy
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 27, 2026, 10:53 PM EDT
Completed No phase listed Observational

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

NCT00900302
View directory record Official record
Conditions
Cancer
Interventions
protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
Genetic · Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 120 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 10, 2016 · Synced Oct 27, 2026, 10:53 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Intralesional Tetracycline Injection in the Treatment of Chalazia

NCT01763437
View directory record Official record
Conditions
Chalazia, Chalazion
Interventions
Tetracycline
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 27, 2026, 10:53 PM EDT
Recruiting No phase listed Observational

Longitudinal Study of the Porphyrias

NCT01561157
View directory record Official record
Conditions
Acute Porphyrias, Cutaneous Porphyrias
Interventions
Not listed
Lead sponsor
The American Porphyrias Expert Collaborative
Other
Eligibility
1 Minute and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2030
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 27, 2026, 10:53 PM EDT
Recruiting Not applicable Interventional

Battlefield Acupuncture for Pain in Hidradenitis Suppurativa

NCT04218422
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Battlefield Acupuncture, Sham Acupuncture
Procedure
Lead sponsor
Wayne State University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 27, 2026, 10:53 PM EDT
Completed Not applicable Interventional Results available

Topical Keratin in Treating Radiation Dermatitis in Patients With Breast Cancer

NCT03374995
View directory record Official record
Conditions
Breast Carcinoma, Radiation-Induced Dermatitis
Interventions
Best Practice, Quality-of-Life Assessment, Topical Keratin
Other · Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 27, 2026, 10:53 PM EDT
Terminated Not applicable Interventional Results available

Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy

NCT01796977
View directory record Official record
Conditions
Breast Cancer, Reconstructive Breast Surgery
Interventions
OxyGenesys Dissolved Oxygen Dressing, Standard Gauze Dressing
Device
Lead sponsor
Halyard Health
Industry
Eligibility
21 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Chicago, Illinois • St Louis, Missouri • Great Neck, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 27, 2026, 10:53 PM EDT
Completed Phase 2 Interventional Results available

Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)

NCT03531957
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ASN002, Placebo Oral Tablet
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
30
States / cities
Anniston, Alabama • Birmingham, Alabama • Fremont, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 27, 2026, 10:53 PM EDT
Completed Phase 1 Interventional

TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome

NCT02822586
View directory record Official record
Conditions
Mycosis Fungoides, Sézary Syndrome
Interventions
TSEB Therapy, Brentuximab vedotin
Radiation · Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 30, 2019 · Synced Oct 27, 2026, 10:53 PM EDT
Completed Not applicable Interventional Results available

Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care

NCT01716169
View directory record Official record
Conditions
Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa
Interventions
Helicoll, Standard of Care Dressings
Device
Lead sponsor
Stanford University
Other
Eligibility
7 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Oct 27, 2026, 10:53 PM EDT
Terminated Not applicable Interventional Results available

Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer

NCT01897441
View directory record Official record
Conditions
Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
Cyclophosphamide, Cytology Specimen Collection Procedure, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Trastuzumab, Endocrine therapy
Drug · Other · Biological
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 27, 2026, 10:53 PM EDT
Recruiting Phase 2 Interventional

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease

NCT07281456
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Tofacitinib
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 27, 2026, 10:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

DNA, Blood and Skin Cell Repository for Research on ALS and Related Neurodegenerative Disorders at Mayo Clinic Florida

NCT01699451
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 27, 2026, 10:53 PM EDT
Recruiting Not applicable Interventional

CARE-D-FOOT-Nav Pilot

NCT07143175
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU)
Interventions
Comprehensive Assistance and Resources for Effective Diabetic Foot Navigation
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 27, 2026, 10:53 PM EDT
Active, not recruiting Phase 1 Interventional

Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors

NCT05902520
View directory record Official record
Conditions
HNSCC, Melanoma, Gynecologic Cancer, Colorectal Cancer, Lung Cancer, Urogenital Cancer
Interventions
DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2
Biological
Lead sponsor
AgonOx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 27, 2026, 10:53 PM EDT
Completed Phase 1 Interventional

Absorption and Systematic Pharmacokinetics of IDP-121 Lotion in Subjects With Acne Vulgaris

NCT02849860
View directory record Official record
Conditions
Acne
Interventions
IDP-121 Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Austin, Texas • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Oct 27, 2026, 10:53 PM EDT
Recruiting Not applicable Interventional

Sun Exposure and Activities After Skin Cancer: Optimization of mHealth Interventions

NCT07556380
View directory record Official record
Conditions
Melanoma (Skin Cancer)
Interventions
UV Real-Time Alerts, Track Your Sun Protection, Current Conditions, Health Coaching, Action Planning, Core Components
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 27, 2026, 10:53 PM EDT
Not listed Not applicable Interventional

Omega-3 Fatty Acids in Preventing Breast Cancer in Women at High Risk of Developing Breast Cancer

NCT00114296
View directory record Official record
Conditions
Breast Cancer
Interventions
omega-3 fatty acid
Dietary Supplement
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 27, 2026, 10:53 PM EDT